Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AbbVie, accommodate, adult, AKYNZEO, ALOXI, aprepitant, AstraZeneca, AVASTINTM, bevacizumab, biological, CINVANTITM, efficiency, Eisai, EMEND, encourage, enterprise, ERP, fluzoparib, furnished, HCl, Helsinn, Heron, insignificant, introduced, LYNPARZA, LYNPARZATM, monotherapy, netupitant, olaparib, orphan, palonosetron, pathway, Pfizer, platinum, Plc, rapidly, regimen, relapsed, resource, responded, Roche, RUBRACA, RUBRACATM, rucaparib, Sandoz, Serono, somatic, talazoparib, veliparib, version, widely
Removed:
approve, eventually, IND, Index, investigational, letter, reference, retained, review, twelve, upfront
Filing tables
Filing exhibits
Related press release
TSRO similar filings
Filing view
External links